Skip to main content

Table 4 Comparison of Progression-free survival times (months) after the first treatment calculated using Kaplan–Meier analysis and groups with Log-rank test

From: Survival in patients with multiple myeloma: evaluation of possible associations with bone marrow fibrosis and investigation of factors independently associated with survival

  n Progression Mean ± Standard Error (95% CI) p
Progression-free survival 59 53 14.07 ± 2.54 (9.09–19.05) N/A
Age     
 < 60 25 23 7.34 ± 2.13 (3.17–11.52) 0.011
 ≥ 60 34 30 18.52 ± 3.75 (11.16–25.87)  
Sex     
 Male 34 30 16.03 ± 3.66 (8.86–23.21) 0.364
 Female 25 23 11.51 ± 3.27 (5.09–17.92)  
Comorbidity     
 No 21 20 10.91 ± 3.48 (4.08–17.73) 0.203
 Yes 38 33 15.78 ± 3.46 (9.00–22.55)  
Type     
 Heavy chain 47 44 9.89 ± 1.99 (6.00–13.78) 0.007
 Light chain 12 9 30.22 ± 8.44 (13.68–46.77)  
Stage     
 Others 16 14 21.98 ± 5.18 (11.82–32.14) 0.024
 Stage III (A/B) 38 37 8.82 ± 2.55 (3.82–13.82)  
Lytic lesion     
 No 15 15 5.67 ± 1.52 (2.69–8.64) 0.692
 Yes 26 26 6.65 ± 2.78 (1.20–12.10)  
Plasmacytoma     
 No 36 32 11.11 ± 2.67 (5.88–16.35) 0.247
 Yes 21 20 17.55 ± 4.73 (8.27–26.83)  
Hypercalcemia     
 No 47 42 13.11 ± 2.78 (7.66–18.57) 0.396
 Yes 8 7 21.63 ± 9.23 (3.53–39.72)  
High creatinine (> 2)     
 No 46 42 13.75 ± 2.68 (8.50–19.01) 0.971
 Yes 13 11 13.69 ± 5.81 (2.31–25.08)  
Bone marrow fibrosis level     
 0 14 12 20.55 ± 6.59 (7.64–33.47) 0.220
 1–4 44 40 12.61 ± 2.73 (7.26–17.95)  
  1. p values marked with bold indicate statistically significant differences between the groups